Expression of lymphoid enhance factor 1 in acute myelogenous leukemia patients with intermediate-risk and its clinical significance

Abstract

Objective To quantitatively analyze the mRNA expression level of lymphoid enhance factor 1 (LEF-1) in bone marrow mononuclear cells of patients with acute myeloid leukemia (AML) at intermediate-risk after initial diagnosis and chemotherapy, and to analyze its clinical significance. Methods The real-time fluorescence quantitative polymerase chain reaction (RT-PCR) was used to measure the expression level of LEF-1 gene in AML patients at intermediate-risk after initial diagnosis and chemotherapy, and its relationship with effectiveness and survival were analyzed. Results The LEF-1 mRNA level in preliminarily diagnosed patients with AML was significantly higher than that in control arm [0.005 19 (0.000 15-0.092 07) vs. 0.001 01 (0.000 09-0.002 33)], and the difference was statistically significant (u= 134.50, P < 0.01). The LEF-1 mRNA level in patients after chemotherapy was significantly declines as compared to that in patients before chemotherapy [0.001 07 (0.000 08-0.007 44) vs. 0.005 19 (0.000 15-0.092 07)], and the difference was statistically significant (u= 317.00, P < 0.01) and LEF-1 mRNA expression level before chemotherapy in complete remission (CR) patients was significantly higher than that in non-CR patients [(0.011 08 (0.001 64-0.092 07) vs. 0.001 10 (0.000 15-0.009 16)], and the difference was statistically significant (u= 19.00, P < 0.01). High LEF-1 expression predicted a significantly better overall survival in AML patients with intermediate-risk cytogenetics (χ2= 4.549, P= 0.033). Conclusions LEF-1 may be involved in the development and progression of AML at intermediate-risk patients and is closely related to tumor burden and treatment efficacy. LEF-1 may be a good predictor of better prognosis and a novel target for therapeutic effect. Key words: Leukemia, myeloid, acute; Polymerase chain reaction; Lymphoid enhance factor 1; Prognosis